Ascendis Pharma A (ASND) Common Equity (2012 - 2026)
Ascendis Pharma A (ASND) posted Common Equity of $571.3 million for Q1 2026, up 401.42% sequentially from -$189.5 million in Q4 2025, and up 386.14% YoY from $117.5 million in Q1 2025.
Ascendis Pharma A (ASND) Common Equity (2012 - 2026) Analysis & Trends
Ascendis Pharma A has reported Common Equity for 15 years, with the latest figure at $571.3 million in Q1 2026.
- Quarterly Common Equity rose 386.14% year-over-year to $571.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $571.3 million (up 386.14% YoY) and the FY2025 annual result came in at -$189.5 million, down 107.41% from the prior year.
- Common Equity advanced to $571.3 million in Q1 2026 per ASND's latest filing, from -$189.5 million in the prior quarter.
- Over five years, Common Equity peaked at $2.6 billion in Q4 2024 and troughed at -$345.8 million in Q2 2024.
- A 5-year average of $220.7 million and a median of -$79.9 million in 2023 frame the typical range for Common Equity.
- The widest YoY moves for Common Equity: up 1730.95% in 2024, down 589.79% in 2024.
- Over 5 years, Common Equity stood at $268.7 million in 2022, then plunged by 158.34% to -$156.8 million in 2023, then surged by 1730.95% to $2.6 billion in 2024, then slumped by 107.41% to -$189.5 million in 2025, then soared by 401.42% to $571.3 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $571.3 million, -$189.5 million, and -$203.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Ascendis Pharma A | 15.40 Bn | 14.73 Bn | 268.20 Mn | 571.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 571.29 Mn |
| Dec 31, 2025 | -189.53 Mn |
| Sep 30, 2025 | -203.50 Mn |
| Jun 30, 2025 | -212.32 Mn |
| Mar 31, 2025 | -199.66 Mn |
| Dec 31, 2024 | 2.56 Bn |
| Sep 30, 2024 | -106.88 Mn |
| Jun 30, 2024 | -345.82 Mn |
| Mar 31, 2024 | -258.75 Mn |
| Dec 31, 2023 | -156.76 Mn |
| Sep 30, 2023 | -79.94 Mn |
| Jun 30, 2023 | 70.61 Mn |
| Mar 31, 2023 | 179.46 Mn |
| Dec 31, 2022 | 268.68 Mn |
| Sep 30, 2022 | 455.29 Mn |
| Jun 30, 2022 | 648.60 Mn |
| Mar 31, 2022 | 755.13 Mn |
| Dec 31, 2021 | 1.01 Bn |
| Sep 30, 2021 | 1.17 Bn |
| Jun 30, 2021 | 827.92 Mn |